Glaucoma | Ophthalmology Innovation Source

Biopharma Companies of All Stages Shine in OIS Showcase

Biopharmaceutical development has gone well beyond the drugs themselves to mechanisms and platforms that aim to deliver those drugs more effectively and precisely than existing platforms, as nearly 800 attendees at the Ophthalmology Innovation Summit in Chicago heard during the BioPharma Showcase. Read the key takeaways below on the companies that presented, and watch the…

Mobius Therapeutics Investigates Extending Mitosol Platform

Ed Timm, President and CEO of Mobius Therapeutics LLC, provided an update on the investigations into extending the company’s Mitosol platform, presently used to administer mitomycin-C in ab externo glaucoma surgery. Mitosol avoids the issues of sterility and stability of mitomycin-C made in compounding pharmacies. Mobius is investigating the use of the platform in refractive…

GrayBug With Preclinical Work On Microparticle Anti-VEGF Compound GB-102

GrayBug LLC is conducting preclinical work on its microparticle anti-VEGF compound GB-102, an extended-release injectable for wet AMD. The platform encapsulates the active drug ingredient in microparticles that degrade over time once injected into the eye to gradually release the agent. In mouse studies, GB-102 has been shown to prolong suppression of choroidal neovascularization 4.5…

Allysta Pharmaceuticals Developing Multi-Kinase Inhibitor To Treat Glaucoma

Aly1337 is a novel, small-molecule multi-kinase inhibitor that Allysta Pharmaceuticals Inc. is developing to treat glaucoma, said Henry Hsu, MD, Founder and CEO. Kinase, particularly Roh kinase, plays a key role in preventing aqueous outflow through the trabecular meshwork, thus contributing to increasing intraocular pressure. Among the kinases Aly1337 targets is kinase LRRK2, which, according…

Aerie Pharmaceuticals With Two ROCK Inhibitors In Development

Publicly traded Aerie Pharmaceuticals Inc. has two Rho kinase inhibitors, or ROCK inhibitors, in development, CEO Vicente Anido, Jr, PhD, reported Rhopressa which is in phase III studies, and Roclatan, a Rhopressa-latanoprost combination that is entering a Phase III trail. ROCK inhibitors have been known to improve aqueous outflow through the trabecular meshwork and, possibly, improve…

How Alcon and Google Could Change The Contact Lens

Moderator: Gilbert H. Kliman, MD Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of healthcare opportunities, with a special interest in ophthalmology and digital health. View Full Profile Panelists: Brian P. Otis, PhD Dr. Brian Otis is the founder of Google [x]’s smart contact lens…

Anido Guides Aerie’s Push To Be A “Very Big Player” In Glaucoma

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 009″] Vicente Anido, Jr., PhD’s career has taken him through large companies and private start-ups. He’s taken life science companies public on two occasions, and he’s seen nearly every perspective of the ophthalmology industry. Today, Anido expects big things for Aerie Pharmaceuticals, a clinical-stage pharmaceutical company with two promising treatments for…

EyeSonix

Donald Schwartz talks about TUG, which is the only ultrasound treatment designed for all open angle glaucoma. Presenter: Donald Schwartz Donald Schwartz is a comprehensive ophthalmologist in practice in Long Beach CA. He is on the clinical faculty of both USC and UC Irvine where he has taught cataract surgery and optics and refraction for…

Review of the Ophthalmology Innovation Cycle – Panel Discussion

Join William J. Link, PhD as he leads a panel discussion on the risks associated with the innovation cycle and the lessons learned. Moderators: William J. Link, PhD Bill was Founder, Chairman and CEO of Chiron Vision, sold in 1997. Bill founded and served as President of American Medical Optics (AMO), sold in 1986. View…

2013 Ophthalmology Innovation Summit Innovator Awards

William J. Link PhD, Managing Director for Versant Ventures, announces the winners of the 2013 OIS Innovator Award. Describing the caliber and achievement that merits this award, Bill recognizes Thomas Burns, President & CEO for Glaukos, and Richard Hill MD, Co-Founder for Glaukos, for their high impact ophthalmic innovations that have successfully improved the lives…

The NEI Continues to Explore the Root Cause of Glaucoma

Ophthalmic Innovation 2013 – “A View from the NEI” Paul Sieving, Director for the National Eye Institute, leads the attendees at the 5th Annual Ophthalmology Innovation Summit @ AAO through a overview of the organizations goals and accomplishments. Sharing the institute’s focus on discovering the cause of Glaucoma, Paul continues to share highlights on the…

AMAO76 Alleviates the Pressure for Amakem Therapeutics

Jack Elands, CEO for Amakem, talks about his company’s focus on a localized drug action platform, and details the company’s feature glaucoma product to lower intraocular pressure designated, AMAO76 rokinase inhibitor. Presenter: Jack Elands Dr. Jack Elands has been the CEO of Amakem since its inception. Before, Jack was CBO of Silicos, an informatics based…